Harvard Bioscience Inc
HBIO· Nasdaq
HBIOHarvard Bioscience Inc
Released Nov 7, 2024, before the open
10-Q filed Nov 8, 2024, 39 days after period end · 0001171843-24-006181
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $21.97M | $25.36M | $26.92M | $29.66M |
| Net Income | -$4.80M | -$1.24M | -$3.41M | -$170.00K |
| EPS Diluted |
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR
| -$0.11 |
| -$0.03 |
| -$0.08 |
| $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
